Manning & Napier Advisors LLC Raises Stock Position in Pfizer Inc. $PFE

Manning & Napier Advisors LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 58.3% during the first quarter, Holdings Channel.com reports. The institutional investor owned 77,663 shares of the biopharmaceutical company’s stock after buying an additional 28,590 shares during the period. Manning & Napier Advisors LLC’s holdings in Pfizer were worth $2,181,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in PFE. Brighton Jones LLC lifted its holdings in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC raised its stake in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares in the last quarter. United Bank lifted its position in Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after acquiring an additional 6,415 shares during the last quarter. Sei Investments Co. lifted its holdings in shares of Pfizer by 31.5% in the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after purchasing an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC boosted its holdings in shares of Pfizer by 45.3% in the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after acquiring an additional 31,896 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.2%

Shares of PFE opened at $24.21 on Monday. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The company has a market capitalization of $138.01 billion, a P/E ratio of 18.48 and a beta of 0.35. The stock has a 50-day moving average price of $25.37 and a 200 day moving average price of $26.19.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio is currently 131.30%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. FDA approved PADCEV plus Keytruda for muscle-invasive bladder cancer, expanding the label for a key Pfizer/Astellas regimen and potentially opening the door to more sales in oncology. Article: U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
• Positive Sentiment: Pfizer’s oncology story also got incremental attention from a completed lorlatinib lung cancer study and other clinical updates, which keep investors focused on the company’s pipeline rather than only its mature products. Article: Pfizer’s Lorlatinib Lung Cancer Study Wraps Up, Offering Fresh Signals for PFE Investors
• Neutral Sentiment: Bank of America lowered its price target on Pfizer to $26 from $27 while keeping a neutral rating, signaling limited upside but no major change in its overall stance. Article: Pfizer had its price target lowered by Bank of America Corporation from $27.00 to $26.00.
• Negative Sentiment: Several market commentary pieces highlighted concerns about Pfizer’s growth outlook and mixed second-quarter expectations, including skepticism about how quickly Seagen-related benefits will show up in results. Article: Pfizer Poised for Mixed Second Quarter, RBC Says

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on PFE shares. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. CICC Research initiated coverage on shares of Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target for the company. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a research report on Tuesday, June 9th. Guggenheim raised their price target on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Finally, Citigroup boosted their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus price target of $28.56.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.